SEC Filing Summary: CryoLife, Inc. (Form 10-K)
Business Context and Reporting Period
Company: CryoLife, Inc. (Note: Input metadata referenced "ARTIVION, INC." but the filing text identifies the registrant as CryoLife, Inc.)
Reporting Period: Fiscal year ended December 31, 2001.
Business Overview: CryoLife is a leader in the preservation of human tissues for cardiovascular, vascular, and orthopaedic transplant applications. The company also develops and commercializes implantable medical devices, including BioGlue(R) Surgical Adhesive and SynerGraft(R) tissue-engineered heart valves and vascular grafts. Operations are primarily based in the United States, with international distribution in Europe, Canada, and other regions.
Key Financial Metrics (Year Ended Dec 31, 2001)
| Metric | 2001 | 2000 | Change |
|---|---|---|---|
| Total Revenues | $87.7 million | $77.1 million | +14% |
| Net Income | $9.2 million | $7.8 million | +17% |
| Earnings Per Share (Diluted) | $0.47 | $0.41 | +15% |
| Operating Cash Flow | $6.5 million | $10.3 million | -37% |
| Working Capital | $66.7 million | $69.1 million | -3% |
| Total Debt (Long-term + Current) | $11.6 million | $11.5 million | ~0% |
| Current Ratio | 5:1 | 8:1 | Decreased |
Revenue Composition (2001):
- Human Tissue Preservation Services: $75.6 million (86% of total)
- Implantable Medical Devices (BioGlue & Bioprosthetics): $11.1 million (13% of total)
- Research Grants: $0.99 million
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a 65% increase in BioGlue Surgical Adhesive sales ($10.6 million) and a 39% increase in orthopaedic tissue preservation revenues ($22.5 million). Cardiovascular preservation revenues declined 4% due to a decrease in tissue procurement.
- Cost Structure: Cost of products as a percentage of revenue improved to 49% from 62% in 2000, attributed to a favorable product mix (higher margin BioGlue sales) and the exit of the low-margin single-use medical device business (IFM).
- Operating Expenses: General, administrative, and marketing expenses rose 18% to $33.8 million, largely due to the full-year operation of the European headquarters and increased marketing support. R&D expenses decreased 9% to $4.7 million following the wrap-up of BioGlue clinical trials.
- Non-Recurring Items: The company recorded a $1.6 million loss on marketable securities deemed "other than temporary," partially offset by a $0.7 million gain from the reversal of a reserve on a note receivable from the sale of IFM assets.
Guidance, Outlook, Risks, and Contingencies
Outlook & Strategy:
- BioGlue Expansion: Following FDA approval in December 2001 for use in open surgical repair of large vessels, the company anticipates a significant shift in revenue composition with BioGlue sales expected to grow substantially.
- Facility Expansion: A 100,000 square foot addition to corporate headquarters and manufacturing facilities was completed in early 2002 to support BioGlue and SynerGraft production.
- ACT Technology: The company is seeking corporate collaboration or private placement funding for its Activation Control Technology (ACT) via its subsidiary, AuraZyme, to avoid direct R&D expenditure.
Risks & Contingencies:
- Legal Proceedings: Colorado State University Research Foundation (CSURF) has sued CryoLife alleging breach of a technology license agreement regarding the SynerGraft process. An adverse decision could have a material adverse effect.
- Infectious Disease: In late 2001 and early 2002, 14 post-transplant infections (one fatal) were reported linked to CryoLife tissues, raising concerns about demand and potential procedural changes.
- Regulatory: Significant dependence on FDA and foreign regulatory approvals for new products (e.g., porcine heart valves in the U.S.).
- Liquidity: While current cash and marketable securities are sufficient for the next 12 months, future liquidity depends on FDA approvals, market acceptance, and the outcome of litigation.
Investor Verification Checklist
- Post-Transplant Infection Impact: Verify the extent of demand reduction or pricing pressure resulting from the reported infections in late 2001/early 2002.
- CSURF Litigation Status: Monitor the progress of the lawsuit regarding SynerGraft technology royalties and patent ownership.
- BioGlue Commercialization: Assess the actual uptake of BioGlue following the December 2001 FDA approval for large vessel repair.
- ACT Funding: Confirm whether AuraZyme has secured the necessary external funding to develop the Activation Control Technology.
- Debt Covenants: Review compliance with the Term Loan covenants, specifically tangible net worth and leverage ratios, given the recent capital expenditures.